Journal
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Volume 58, Issue 9, Pages 2558-2569Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/anie.201805246
Keywords
photodynamic therapy; photosensitizers; phototherapy; theranostics; therapeutic beacons
Categories
Funding
- Natural Sciences and Engineering Research Council of Canada [RGPIN-2015-03688]
- Canadian Institutes of Health Research [FDN-154326]
- Canada Foundation for Innovation [21765]
- Princess Margaret Cancer Foundation
Ask authors/readers for more resources
Photodynamic therapy (PDT) is a clinical treatment in which a light-absorbing drug called a photosensitizer (PS) is combined with light and molecular oxygen to generate cytotoxic singlet oxygen. PDT provides additional tissue selectivity compared to conventional chemotherapy as singlet oxygen is generated only in areas in which PS accumulates and that are simultaneously illuminated by a light source with sufficient irradiance and dose. Early PDT beacons built on this concept by adding an analyte-responsive element that simultaneously turns on PDT and fluorescence, providing both an additional layer of selectivity and real-time feedback of the PS's activation state. More recent PDT beacons have expanded this idea, with new methods now available for sensing analytes, generating singlet oxygen, and reporting treatment status. In this Minireview, we consider developments in advanced activation strategies implemented in therapeutic and theranostic beacons.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available